MEGF10 and muscle tissue disorder: Furthermore, investigation of serotonin pathway modulators at lower concentrations should also be investigated, since recent study showed that application of 0.1–1 μM SSRI sertraline or escitalopram was not toxic and improved survival in a zebrafish model of MEGF10 myopathy (Saha et al., 2019); therefore, we do not exclude beneficial effect of serotonin modulation in DMD or other muscular disorders.